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Abstract
AIM
To investigate whether immune mediated diseases 
(IMD) are more frequent in patients with inflammatory 
bowel disease (IBD).
METHODS
In this population based registry study, a total of 47325 
patients with IBD were alive and registered in the 
Danish National Patient Registry on December 16, 2013. 
Controls were randomly selected from the Danish Civil 
Registration System (CRS) and matched for sex, age, 
and municipality. We used ICD 10 codes to identify the 
diagnoses of the included patients. The IBD population 
was divided into three subgroups: Ulcerative colitis (UC), 
Crohn’s disease (CD) and Both the latter referring to 
those registered with both diagnoses. Subsequently, 
odds-ratios (OR) and 95%CI were obtained separately 
for each group and their respective controls. The use of 
Bonferoni post-test correction adjusted the significance 
level to P < 0.00125. P -values were estimated using 
Fisher’s exact test.
RESULTS
There were significantly more women than men in the 
registry, and a greater percentage of comorbidity in the 
IBD groups (P  < 0.05). Twenty different IMDs were all 
significantly more frequent in the IBD group. Sixteen 
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were associated with UC versus twelve with CD. In 
both UC and CD ORs were significantly increased (P 
< 0.00125) for primary sclerosing cholangitis (PSC), 
celiac disease, type 1 diabetes (T1D), sarcoidosis, 
asthma, iridocyclitis, psoriasis, pyoderma gangren-
osum, rheumatoid arthritis, and ankylosing spondylitis. 
Restricted to UC (P  < 0.00125) were autoimmune 
hepatitis, primary biliary cholangitis, Grave’s disease, 
polymyalgia rheumatica, temporal arteritis , and atro-
phic gastritis. Restricted to CD (P < 0.00125) were 
psoriatic arthritis and episcleritis. Restricted to women 
with UC (P < 0.00125) were atrophic gastritis, rhe-
umatoid arthritis, temporal arteritis, and polymyalgia 
rheumatica. Restricted to women with CD were epi-
scleritis, rheumatoid arthritis, and psoriatic arthritis. 
The only disease restricted to men (P < 0.00125) was 
sarcoidosis. 
CONCLUSION
Immune mediated diseases were significantly more 
frequent in patients with IBD. Our results strengthen 
the hypothesis that some IMDs and IBD may have 
overlapping pathogenic pathways.
Key words: Immune mediated diseases; Ulcerative 
colitis; Risk; Prevalence; Registry; Chronic inflammatory 
diseases; Autoimmune diseases; Inflammatory bowel 
disease; Crohn’s disease; extraintestinal manifestations
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Essential to inflammatory bowel disease (IBD) 
pathogenesis are environmental factors, altered gut 
microbiota and genetic susceptibility. The latter causing 
impairment of barrier function, autophagy, and Th1, 2 
and 17 cell responses. Interestingly, these mechanisms 
are also thought important in other immune mediated 
diseases, as is the overlap of susceptibility genes. 
Besides the classic extraintestinal manifestations, 
we found a variety of immune mediated diseases to 
be more frequent in individuals with IBD. Physicians 
should be aware of this when treating these patients. 
Furthermore, these findings support the hypothesis 
that immune mediated diseases may have overlapping 
pathogeneses. Thus, understanding IBD might help us 
understand other immune mediated diseases and vice 
versa.
Halling ML, Kjeldsen J, Knudsen T, Nielsen J, Koch Hansen L. 
Patients with inflammatory bowel disease have increased risk of 
autoimmune and inflammatory diseases. World J Gastroenterol 
2017; 23(33): 6137-6146  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v23/i33/6137.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i33.6137
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are two 
distinct types of chronic inflammatory bowel diseases. 
The insight into etiology factors and the complex 
pathogenetic process is not yet fully understood. The 
diseases are often diagnosed in young individuals and 
recent studies report increasing incidences of both 
UC and CD, not only in Denmark but globally[1]. It 
has been suggested that inflammatory bowel disease 
(IBD) may be due to an inappropriate inflammatory 
response to the intestinal flora in genetically suscep­
tible individuals. So far, several susceptibility genes 
have been identified[2]. Many of these are also found 
in other immune mediated diseases (IMDs), indicating 
overlaps between pathogenic pathways. The identi­
fied risk genes in IBD are involved in maintaining 
normal microbial gut homeostasis and adequate im­
mune response[3,4]. Mutations in these may impair 
mechanisms essential to innate and adaptive immune 
response, i.e. weakened mucosal barrier, a decrease of 
antibacterial agents, impaired autophagy and antigen 
recognition. Mutations may also cause an imbalance 
of pro­ and anti­inflammatory cytokines related to 
the regulation of Th1, 2 and 17 in particular[5]. CD 
is considered Th1 mediated thus characterized by 
interferon gamma, tumor necrosis factor alpha, and IL 
12. UC is associated with a Th2 response where IL 4, 5, 
10 and 13 are dominant. The Th17 response is present 
in both CD and UC but most pronounced in CD. It 
is characterized by IL 17 and 23 production. Th17 
can also produce interferon gamma like Th1[5­8]. It is 
suggested that disturbances in these mechanisms may 
cause a loss of self­tolerance leading towards chronic 
inflammation or autoimmunity[9­12].
The gut microbiota of patients with IBD has been 
shown to contain less diversity, a reduced number of 
bacteria, and an altered microbial metabolite profile 
compared to healthy individuals[13]. Environmental 
factors, i.e. medication (antibiotics, non­steroid anti­
inflammatory drugs and hormones), diet, geography, 
and previous infections might influence this[4]. A 
similar etiology is believed to exist in other IMDs, 
i.e. rheumatoid arthritis, ankylosing spondylitis, mu­
ltiple sclerosis, type 1 diabetes (T1D), and celiac 
disease[14,15].
It has become clear, that patients with an existing 
IMD are more likely to develop other IMDs, this is 
more evident in females than in males[16]. Apart from 
the extraintestinal manifestations of IBD, little is known 
about the association between IBD and other IMDs.
Only a few large population based studies on the 
subject exist. The results of these suggest that IBD is 
associated with asthma, rheumatoid arthritis, psoriasis, 
multiple sclerosis, autoimmune thyroiditis, T1D, and 
vasculitis[17­22]. Different study designs, varying validity 
of diagnoses, population sizes and confounders, i.e. 
ethnicity, economic and social status, all make the 
findings of these studies difficult to interpret.
In Denmark healthcare is free and all contacts to 
hospitals are registered on an individual basis based 
on a civil registration number together with diagnosis 
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and procedural codes. This allows a unique access to 
information not confounded by economic and social 
status.
The aim of this study was to examine if IMDs 
are more frequent among patients with CD and UC 
compared to the background population. 
MATERIALS AND METHODS
This was a cross­sectional study including all living 
patients with IBD who were matched with a control 
group to compare the point­prevalence of specific 
IMDs.
Identification of patients and controls
The Danish National Patient Registry include all 
contacts within the healthcare system both in­hospital, 
since 1977, and in outpatient settings since 1994. Data 
were retrieved on December 16, 2013 and included all 
patients alive registered with a diagnosis compatible 
with CD and UC. Patients were identified using the ICD 
10 codes: CD K50.0­K50.9; UC, K51.0­K51.9). ICD 10 
codes including “other” or “unspecified” were excluded 
to avoid inclusion of non­specific diseases and incorrect 
diagnosis codes. 
The Danish Civil Registration System (CRS) in­
cludes all Danish inhabitants and each person has a 
unique 10­digit identification number. The CRS includes 
demographic data e.g. name, sex, date of birth, and 
death[23]. All IBD patients were paired (2:1) with 
random controls identified in the CRS and matched 
by sex, age (± 1 year) and municipality. Demographic 
data presented are based on data from the CRS.
The selected forty IMDs are all considered to be of 
either autoimmune or inflammatory origin. The same 
criteria were used for the IMDs. ICD 10 codes for the 
IMDs are listed in the Supplementary Table 1. 
To assess comorbidity we used the Charlson 
comorbidity index which has been developed to 
estimate 1­year mortality in cancer patients. It is also 
useful in research to identify possible confounding 
diseases. It includes a number of systemic diseases 
associated with increased mortality, i.e. organ failure, 
AIDS, and cancer[24].
Ethics
This study was approved by the Danish Data Protection 
Agency (approval # 2013­41­1596). Approval from the 
Ethics Committee was not needed as this is a registry 
study.
Statistical analysis
The occurrence of IMDs was obtained separately for 
each group. Then OR and 95%CI were calculated. 
Fisher’s exact test was used to calculate p­values.
We used the Bonferroni post­test correction to 
reduce the likelihood of false positives. We did 40 
comparisons (the 40 IMDs investigated) and adjusted 
the significance level accordingly to p < 0.00125. 
Calculations was made using STATA version 13.0 
(StataCorp LP, TX, United States).
RESULTS
A total of 47325 patients were alive and registered 
with IBD on December 16, 2013. A total of 92839 
controls were identified.
CD was registered in 13343 patients, UC in 31066, 
and 2916 were registered with both diagnoses. A 
total of 92839 controls were found for the IBD group, 
26172 for CD, 60951 for UC and 5716 for those with 
both diagnoses. Due to the matching criteria, five IBD 
patients had only one or no controls.
There was an excess of women in all IBD groups, 
most pronounced in CD (p < 0.05). The mean age 
at onset of disease was significantly higher in UC. 
Comorbidity was most frequent in those with either UC 
or CD (p < 0.05). See Table 1.
Twenty out of forty IMDs had significantly increased 
ORs in the IBD groups compared to their controls (p < 
0.00125). Sixteen IMDs were associated with UC and 
twelve with CD. See Tables 2 and 3.
Seven of the IMDs were considered rheumatologic 
diseases, included ankylosing spondylitis, rheumatoid 
arthritis, psoriatic arthritis, polymyalgia rheumatic, 
temporal arteritis, polyarteritis nodosa, and Churg 
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Table 1  Participants’ demographic data
Variables IBD Control UC Control CD Control Both1 Control
n 47325 92839 31066 60951 13343 26172 2916 5716
Female 54%      55%      53% 53% 58% 58% 56% 56%
Male 46%      45%      47% 47% 42% 42% 44% 44%
Mean age at entry, yr 53 53 55 55 49 49 47 47
Mean age at onset of IBD, yr 42 - 44 - 37 - 34 -
Mean duration of IBD at entry, yr 10 - 9 - 10 - 11 -
Comorbidity 02 77%      83% 76.50% 82.00% 77% 85% 82% 87%
Comorbidity 1-2 18% 13.50%  18.00% 14% 18% 12% 15% 10%
Comorbidity ≥ 3   5%   3.50%   5.50% 4%   5%   3%   3%   3%
1Patients registered with both CD and UC; 2No. of comorbidities at onset of IBD according to the Charlson comorbidity index. CD: Crohn’s disease; UC: 
Ulcerative colitis; IBD: Inflammatory bowel disease.
Halling ML et  al. Autoimmune diseases associated with IBD
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Seven IMDs were only significant in women. While 
only one was restricted to men. See Table 4.
In general, the same pattern is seen in those 
registered with both CD and UC. 
We did not observe any OR below one, neither did 
we record any cases of Sjögren’s syndrome, inclusion 
body myositis, eosinophilic esophagitis, or autoimmune 
adrenalitis.
DISCUSSION
In this study, we documented an increased frequency 
Strauss Syndrome.
Five IMDs were gastrointestinal including celiac 
disease, atrophic gastritis, primary sclerosing chol­
angitis, primary biliary cholangitis, and autoimmune 
hepatitis.
The remaining IMDs were T1D, Grave’s disease, 
pyoderma gangrenosum, psoriasis, iridocyclitis, epis­
cleritis, sarcoidosis, and asthma. 
There was a trend towards significance (p = 
0.00125­0.05) for Wegener’s granulomatosis, chori­
oretinitis, vitiligo, lichen ruber planus, scleroderma, and 
multiple sclerosis.
Table 2   Number of immune mediated diseases
Disease IBD Control CD Control UC Control Both1 Control
Primary sclerosing cholangitis   257       4   35     1   192       2   30   1
Pyoderma gangrenosum   193       8   60     1     97       7   36   0
Autoimmune hepatitis   124     35   15   11     96     22   13   2
Celiac disease   280     92 133   30   132     58   15   4
Ankylosing spondylitis   431   151 189   32   201   102   41 17
Churg Strauss syndrome     14       5     4     1       8       4     2   0
Primary biliary cholangitis     71     32   11     6     53     25     7   1
Episcleritis     56     33   25     9     23     21     8   3
Iridocyclitis   419   295 148   82   230   188   41 25
Atrophic gastritis     60     47   16   11     42     34     2   2
Psoriasis   378   345 148   99   200   229   30 17
Polyarteritis nodosa     42     38   15     9     24     27     3   2
Rheumatoid arthritis   446   401 119 110   250   311   32 25
Type 1 diabetes 1682 1464 359 431 1002 1180 103 71
Sarcoidosis   141   122   29   38     79     94   14   9
Asthma 1140   981 337 363   568   695   76 82
Giant cell arteritis   193   156   37   46   116   141 3   6
Psoriatic arthritis   316   249   81   93   147   206 21 17
Grave's disease   817   581 141 207   394   561 46 49
Polymyalgia rheumatica   468   320   72 122   242   324     6 22
1Patients registered with both CD and UC. CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
Table 3  Odds-ratios for immune mediated diseases, in patients with inflammatory bowel disease
Disease IBD 95%CI UC 95%CI CD 95%CI Both1 95%CI
Primary sclerosing cholangitis 126.7a   47.2-340.3 189.5a   47.0-763.4   68.8a     9.4-502.6 59.4a     8.1-436.2
Pyoderma gangrenosum   47.5a 23.4-96.4   27.3a 12.7-58.7 118.2a   16.4-853.3 36/0a,2
Autoimmune hepatitis     7.0a   4.8-10.1     8.6a   5.4-13.6     2.7b 1.2-5.8 12.8a   2.9-56.8
Celiac disease     6.0a 4.7-7.6     4.5a 3.3-6.1     8.8a   5.9-13.0   7.4a   2.4-22.3
Ankylosing spondylitis     5.6a 4.7-6.8     3.9a 3.1-4.9   11.7a   8.1-17.1   4.8a 2.7-8.4
Churg Strauss syndrome     5.5a   2.0-15.3     3.9b   1.2-13.0 -c -c
Primary biliary cholangitis     4.4a 2.9-6.6     4.2a 2.6-6.7     3.6b 1.3-9.7 13.8b     1.7-111.9
Episcleritis     3.3a 2.2-5.1     2.1b 1.2-3.9     5.5a   2.5-11.7   5.2b   1.4-19.8
Iridocyclitis     2.8a 2.4-3.3     2.4a 2.0-2.9     3.6a 2.7-4.7   3.2a 2.0-5.4
Atrophic gastritis     2.5a 1.7-3.7     2.4a 1.5-3.8     2.9b 1.3-6.2 -c
Psoriasis     2.2a 1.9-2.5     1.7a 1.4-2.1     3.0a 2.3-3.8   3.5a 1.9-6.5
Polyarteritis nodosa     2.2a 1.4-3.4     1.7b 1.0-3.0     3.3b 1.4-7.5 -c
Rheumatoid arthritis     1.8a 1.5-2.0     1.6a 1.3-1.9     2.1a 1.6-2.8   2.5a 1.5-4.2
Type 1 diabetes     1.7a 1.6-1.9     1.7a 1.6-1.8     1.7a 1.4-1.9   2.9a 2.2-3.9
Sarcoidosis     1.7a 1.3-2.2     1.7a 1.2-2.2 -c   3.1b 1.9-4.8
Asthma     1.7a 1.6-1.9     1.6a 1.4-1.8     1.8a 1.6-2.1   1.8a 1.3-2.5
Giant cell arteritis     1.6a 1.3-2.0     1.6a 1.3-2.1     1.6b 1.0-2.4 -c
Psoriatic arthritis     1.5a 1.3-1.8     1.4b 1.1-1.7     1.7a 1.3-2.3   2.4b 1.3-4.6
Grave's disease     1.4a 1.3-1.6     1.4a 1.2-1.6     1.3b 1.1-1.7   1.9b 1.2-2.8
Polymyalgia rheumatica     1.3a 1.2-1.5     1.5a 1.2-1.7 -c -c
aP < 0.00125; bP = 0.00125-0.05; cP > 0.05; 1Patients registered with both CD and UC; 2No. of cases in IBD cohort/No. of cases in control cohort. CD: Crohn’s 
disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
Halling ML et  al. Autoimmune diseases associated with IBD
6141 September 7, 2017|Volume 23|Issue 33|WJG|www.wjgnet.com
of twenty IMDs in patients with IBD compared to 
matched cohorts. 
Although most of the IMDs are considered to be 
Th1 mediated, UC was associated with more IMDs 
than CD. The presence of Th17 cells in UC and their 
ability to induce a Th1 response might explain this. 
Another explanation might be that certain susceptibility 
genes can act differently depending on the setting[25]. 
A gene might increase the risk of one disease while 
reducing the risk of others[25­27].
Extraintestinal manifestations
Ankylosing spondylitis, pyoderma gangrenosum, psori­
asis, iridocyclitis, episcleritis, and primary sclerosing 
cholangitis (PSC) are all well described in IBD[28]. Thus 
the significant associations were expected. Except from 
PSC, these will not be discussed further.
Primary sclerosing cholangitis and gastrointestinal 
immune mediated diseases
PSC is predominant in men and most frequent in UC[29]. 
We found PSC to be associated with both types of IBD 
and both genders. Most striking is the association with 
CD which is less often described. Studies suggest that 
PSC is more frequent when colon is affected and a 
distinct subtype, PSC­IBD has been suggested[30­33]. 
This study does not include data on localization, 
severity or extension. Several PSC risk genes are 
shared with IBD and other IMDs[33,34]. Gene mutations 
influencing IL 10 signaling are identified in CD, UC 
and PSC. The absence of IL 10 can cause severe CD 
due to lack of Th1 and macrophage inhibition[33­35]. 
Interestingly, hepatobiliary inflammation is thought to 
be induced by microbial metabolites and changes in 
the microbiota and this inflammation is linked to the 
FUT2 gene, which is also found in CD[33,34,36].
In contrast to most other studies[18,36,37], we found 
celiac disease to be more frequent in those with IBD 
regardless of type, as did another Danish study[16]. 
Other studies found IBD to be more common in 
patients with celiac disease but not vice versa[38­40]. 
Similarities and differences in pathogeneses might 
explain these conflicting results. Celiac disease is like 
IBD an inflammatory disorder of the intestine, often 
diagnosed in young individuals, more common in 
women, and Th1 mediated. Changes in microbiota 
and dysfunctional IL 18 receptor are also noted in both 
conditions[27,41]. Risk genes of celiac disease shared 
with CD relates to adaptive immunity while those 
shared with UC primarily relates to barrier function. 
Different from IBD is the absence of Th17 response, 
impaired autophagy and while important in celiac 
disease, IL 15 is not that important in IBD[41].
We found autoimmune hepatitis, primary biliary 
cholangitis, and atrophic gastritis to be more common 
in UC only. Again, results from previous studies 
conflict[16,18,21,42­45]. Little is known about the association 
with atrophic gastritis, which to our knowledge is 
unique to this study. Th1, 2 and 17 responses are 
important in IBD, PSC and primary biliary cholangitis 
pathogenesis. Primary biliary cholangitis and IBD have 
overlapping susceptibility genes, which is not the case 
with autoimmune hepatitis[46,47]. The pathogenesis 
of primary biliary cholangitis resembles those of 
autoimmune hepatitis and CD, dysfunctionalities in IL 
12 signaling promotes a Th1 and possibly also a Th17 
response, causing a granulomatous inflammation[47,48].
Endocrine diseases
UC is reported to occur more frequently in family me­
mbers of patients with T1D[18,19,49]. However, three 
studies did not find any association[16,20,21]. This 
study found T1D associated with both UC and CD. 
Confounding due to treatment with corticosteroids is 
unlikely, as the mechanisms in steroid induced diabetes 
resemble those in type 2 diabetes[50,51]. Levels of IL 
18 are elevated in CD and T1D, but not in UC. IL 18 
causes a Th1 response and is likely to affect mucosal 
barrier function too[27,52]. PTPN2 is one of many shared 
risk genes[2,53]. It promotes beta cell apoptosis in T1D 
while causing intestinal barrier dysfunction, impaired 
autophagocytosis, and inhibition of Th17 in IBD[25,54]. 
Changes in the gut microbiota are also suggested to 
trigger T1D[27].
Data on autoimmune thyroiditis and IBD is sparse, 
similarities to IBD limited and only few risk genes 
overlap[55­57]. Restricted to UC only, we found OR 
significantly increased for Grave’s disease. None was 
Table 4  Odds-ratios for immune mediated diseases restricted 
to either gender
Disease Females 95%CI Males 95%CI
IBD
   Episcleritis   3.6a 2.1-6.1 2.9b 1.4-6.1
   Atrophic gastritis   3.5a 2.1-5.9 -c
   Polyarteritis nodosa   2.6a 1.5-4.5 -c
   Rheumatoid arthritis   1.9a 1.6-2.2 1.4b 1.1-1.9
   Giant cell arteritis   1.7a 1.3-2.2 -c
   Psoriatic arthritis   1.6a 1.3-2.0 1.4b 1.1-1.9
   Polymyalgia rheumatica   1.5a 1.3-1.8 -c
   Sarcoidosis   1.5b 1.1-2.2 1.9a 1.3-2.6
UC
   Atrophic gastritis   3.1a 1.7-5.8 -c
   Rheumatoid arthritis   1.7a 1.4-2.1
   Giant cell arteritis   1.7a 1.3-2.3 -c
   Polymyalgia rheumatica   1.6a 1.3-2.0 -c
CD
   Episclerit   5.9a   2.4-15.0 4.5b   1.2-17.5
   Rheumatoid arthritis   2.3a 1.7-3.0 -c
   Psoriatic arthritis   2.0a 1.3-2.8 -c
   Sarcoidosis -c 3.2a 1.6-6.6
Both1
   Iridocyklitis   3.6a 1.9-6.8 2.7 1.2-6.2
   Celiac disease   6.0a   1.9-18.6 3/0b,2
   Autoimmune hepatitis 17.9a     2.3-141.5 7.8b   0.9-69.8
aP < 0.00125; bP = 0.0125-0.05; cP > 0.05; 1Patients registered with both CD 
and UC; 2No. of cases in IBD cohort/No. of cases in control cohort. CD: 
Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
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detected for Hashimoto’s thyroiditis. Similar results are 
reported in two other studies[18,58]. One study reports 
hypothyroidism more common in CD[19]. In addition, 
three other studies did not find any association at 
all[16,17,21]. 
Rheumatic diseases
Rheumatoid arthritis was associated with both UC 
and CD while psoriatic arthritis was restricted to CD. 
Previously published data support this[18,20,21,59]. The 
microbiome of the gut and skin are possible triggers 
in rheumatoid arthritis and psoriatic arthritis[60]. 
Both types of arthritis share characteristics with CD 
in particular. Th1 and 17 are essential in all three 
pathogeneses[2,61­64].
ORs for polymyalgia rheumatica and temporal 
arteritis were significantly increased in the IBD and UC 
group, not in CD. This is supported by one study while 
refuted by another[16,18]. Overlapping susceptibility 
genes suggest that Th1, Th17 and regulatory T cells 
are of importance to the pathogeneses[65]. 
ORs for Churg Strauss Syndrome and polyarteritis 
nodosa were significantly increased in the overall IBD 
group but not in the subgroups. The low number of 
cases calls for careful interpretation and future studies.
Other disorders
In this study, asthma was more common in both UC 
and CD. Both UC and allergic asthma are considered 
Th2 mediated. Also, a Th17 response is described 
in severe asthma[66]. Risk genes are associated with 
IL 13 and 17 production, dysfunctional regulatory T 
cells and regulation of Th1, 2 and 17 responses[26,66]. 
Studies have not found that asthma reduces the 
risk of IBD[67,68], rather the opposite seems more 
likely[17,18,20,21]. 
The association of sarcoidosis and IBD were 
restricted to UC and males with CD. Another study 
confirms the linkage to UC[18]. There is not much 
documentation for this association. The inflammation 
in sarcoidosis is similar to CD; granulomatous; Th1 and 
17 driven; and mutations in NOD2 and IL 23 receptor 
gene are identified[2,69­71].
There were no cases of Sjögren’s syndrome, 
inclusion body myositis, eosinophilic esophagitis, or 
autoimmune adrenalitis. This is unexpected. Some 
case reports have described the coexistence of Sjögren 
and primary adrenocortical insufficiency in IBD 
patients[16,72­74]. One case report describes eosinophilic 
esophagitis and CD[75]. While to our knowledge, no 
association between inclusion myositis and IBD has 
been reported. Although specific ICD 10 codes were 
used misclassification is still possible e.g. autoimmune 
adrenalitis might be registered as Addison’s disease.
Strengths and limitations
The strength of this study is that it includes all pa­
tients alive with CD or UC in Denmark. The Danish 
population is homogenous regarding ethnicity and 
religion. Health care is free to all residents; thus, 
NPR is not biased by inclusion of specific hospitals, 
age groups, insurance policies, social, or financial 
status. As the general practitioners do not provide 
data, diseases not requiring hospital treatment could 
be underrepresented i.e. asthma, Grave’s disease, 
Hashimoto’s thyroiditis, and atrophic gastritis[76].
A limitation of the study is possible bias caused 
by varying validity of the ICD 10 codes. Only few 
Danish studies have addressed this issue. The average 
positive predictive value (PPV) of an ICD 10 diagnosis 
for any medical condition in the NPR varies from 65.5 
% to 81%[76].
However, the completeness is 94% for both UC 
and CD while the PPV of UC and CD is 90% and 97% 
respectively[77]. 
The validity of T1D is like that of IBD, very high[24,78]. 
The PPV of asthma among hospitalized children is 
85% while 65% among adults. However, a sensitivity 
analysis did not find the PPV in adults, low enough to 
nullify the hypothesis[79,80]. As a collective group the 
PPV of connective tissue diseases is reported as high[24]. 
The PPV of rheumatoid arthritis is low[81].
Despite varying validity of ICD 10 codes, most of 
our findings are in alignment with those of the studies 
using algorithms to increase the validity. Important to 
this study, is the occurrence of the classic extraintestinal 
manifestations which indicates that our results are not 
too biased.
Detection bias is another concern. Patients seen on 
regular basis by a physician such as those with IBD are 
more likely to be diagnosed. 
To eliminate confounders like sex, age and geo­
graphy in the IBD group, we used these as matching 
criteria. Information regarding smoking status was not 
available to us, thus no correction was made.
Another confounder is drug induced autoimmunity. 
A wide variety of drugs are suggested to induce 
autoimmunity. Among these are antibiotics, statins, 
methotrexate, thiopurines, and biological agents (anti­
TNF­α agents)[82­88]. Biological agents, which are often 
used to treat IBD, ankylosing spondylitis, psoriasis, 
and rheumatoid arthritis, are paradoxically suggested 
to induce IMDs. No correction was made since we do 
not have data regarding patients’ use of prescribed 
drugs.
While Bonferroni post­test correction reduced 
the risk of false positives, the risk of false negatives 
simultaneously increased. Knowing this, a low number 
of false positives were still preferred in this study.
In conclusion, our study emphasizes that immune 
mediated diseases are more frequent among pa­
tients with CD or UC. Our results strengthen the 
thesis of partially overlapping pathogeneses among 
some immune mediated diseases including IBD and 
emphasized the complexity of IBD pathogenesis. 
Our most important findings are the increased risk of 
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celiac disease and T1D in both UC and CD, but also 
the increased risk of primary sclerosing cholangitis 
in CD although not being limited to CD. Finally, when 
treating patients with UC or CD one should be aware 
of the strong association with other immune mediated 
diseases.
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